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intRoDuction
There are few published studies describing biochemical markers that correlate with the 
severity of anaphylactic reactions during oral food challenges or accidental reactions to 
foods. Identifying patients with increased risk of severe reactions is a priority within the 
field of anaphylaxis. Previous studies have examined laboratory markers such as specific 
immunoglobulin E (IgE; to allergenic foods or components thereof), parameters of the 
basophil activation test, and platelet-activating factor (PAF).
It has been shown that PAF takes part in various inflammatory events and plays a key role 
in the life-threatening events that cause anaphylaxis (1,2). PAF has been shown to be more 
closely correlated to the severity of anaphylactic reactions than histamine or tryptase in 
humans (3,4). PAF mediates reactions causing increased vascular permeability, hypoten-
sion, and bronchoconstriction (5,6).
Anaphylactic responses are influenced by PAF acetylhydrolase (PAF-AH), which catalyzes 
the degradation of PAF to its inactive products. PAF-AH in plasma is probably produced by 
cells from hematopoietic lineage cells (7) Relative deficiency of PAF-AH has been shown to 
lead to an increased risk of life-threatening anaphylaxis (3). In other words, high levels of 
PAF-AH before an anaphylactic reaction will limit the production of PAF during the ongoing 
reaction and thus limit the severity of that reaction. However, the exact mechanism of this 
pathway is unknown.
In human plasma, PAF-AH circulates in complexes with low- and high-density lipoproteins, 
and the main protein component of low-density lipoprotein particles is apolipoprotein 
B-100 (ApoB). A recent study of a pediatric population allergic to peanuts showed a strong 
correlation between PAF-AH activity and the concentration of the more stable ApoB (8). 
Because of inactivation of PAF by PAF-AH, these data suggest a relation between the sever-
ity of allergic reactions and the plasma concentration of ApoB. Thus, the objective of this 
study was to examine serum ApoB as a possible biomarker for the occurrence and severity 
of anaphylactic reactions to foods.
METhOdS
Data and serum samples were collected from the food challenge unit data and serum bank 
at the University Medical Center Groningen (UMCG; 2002-2014). Serum was collected 
before the double-blinded, placebo-controlled food challenge (DBPCFC). The study popula-
tion consisted of children referred to the UMCG for a clinical suspicion of food allergy. No 
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patients were excluded for a history of severe allergic reactions. Patient data were collected 
by history and laboratory analysis was performed as part of routine clinical care. Assenting 
children underwent a DBPCFC with the suspected food using previously described materials, 
methods, and protocols (9). The medical ethics committee of the UMCG deemed that formal 
medical ethical approval was not required for this study. Cases without a matching available 
serum sample or having missing variables necessary for the analysis were excluded. However, 
children with an unknown history of asthma, atopic dermatitis, or rhinoconjunctivitis were 
included in the analysis, and the inclusion of this patient group did not influence the results.
A symptom-based scoring system was used to determine the severity of the most severe 
accidental reaction as obtained from the history and the severity of the DBPCFC reaction 
as observed during the challenge test, as previously described (10). Briefly, the allergic 
symptoms received a score corresponding to the involved organ system. Skin symptoms 
were given a score of 1, upper airway symptoms (eyes, nose, and throat) were given a score 
of 3, lower airway symptoms (lungs) were given a score of 3, gastrointestinal symptoms 
were given a score of 2, and cardiovascular and/or neurological symptoms were given a 
score of 3. The scores of the involved organ systems were added together and the total 
severity score was calculated (range 0-12). Scores of 0 to 2 were considered mild allergic 
reactions, scores of 3 to 6 were considered moderate allergic reactions, and scores of 7 to 
12 were considered severe allergic reactions.
The concentration of ApoB in the serum samples was determined by nephelometry. Linear 
regression analysis was used to examine the association between the concentration of 
ApoB and the severity of the DBPCFC reaction and the severity of the previous most severe 
accidental allergic reaction by history. Logistic regression analysis was used to study the 
relation between the concentration of ApoB and the food challenge outcome. A factor was 
considered a confounder when it changed the B coefficient of the effect of ApoB on the 
severity of anaphylactic reactions by at least 10%. For all tests, a 2-tailed significance level 
of a P value less than 0.05 was used.
RESultS
Eight hundred thirty-seven cases were included in the final analysis. The study popula-
tion consisted of children with a median age of 5.8 years (interquartile range 3.6-10.4), 
of which 62.7% were boys. A history of asthma was reported in 52.0% of children. Most 
of the study population had atopic dermatitis (88.4%) and 41.5% had rhinoconjunctivitis. 
Specific IgE was measured in all subjects and was positive in 82.1% of the children included 
(Table 1 presents additional patient characteristics).
APOLIPOPROTEIN B: A POSSIBLE NEW BIOMARKER FOR ANAPHYLAXIS 81
6
Table 1. Characteristics of the study population. 






Cow’s milk 233 (27.8%)
Egg 111 (13.3%)
Hazelnut 84 (10.0%)
Cashew nut 82 (9.8%)






Lupine seed 1 (0.1%)
Sesame seed 1 (0.1%)
History of atopic dermatitisa
Yes 740 (88.4 %)
No 93 (11.1%)
History of asthmaa
Yes 435 (52.0 %)
No 393 (47.0 %)
History of rhinoconjunctivitisa
Yes 347 (41.5 %)
No 468 (55.9 %)
Food challenge outcome
Positive 466 (55.7 %)
Negative 371 (44.3 %)
N (range) IQR (median)
Apolipoprotein B (g/l) 837 (0.24-1.31) 0.53-0.77 (0.65)
Age (months) 837 (6.00-215.00) 43.00-124.50 (70.00)
Specific IgE (kU/l) 837 (0.10-101.00) 0.56-16.80 (3.31)
Severity of accidental reaction 837 (0-12) 0.00-5.00 (3.00)
Severity of DBPCFC reactionb 466 (1-9) 2.00-5.00 (3.00)
Eliciting dose (mg protein)b 466 (0.58-1925.00) 14.00-350.00 (70.00)
Abbreviations: DBPCFC, double-blinded, placebo-controlled food challenge; IgE, immunoglobulin E; IQR, interquar-
tile range. aMissing data not shown. bSeverity of  DBPCFC reaction and eliciting dose only available for positive food 
challenge outcomes.
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The severity of the accidental reaction by history was inversely associated with the con-
centration of ApoB (B=-0.09, 95% confidence interval [CI]: -2.53 to -0.33, P=0.011). This 
relation was not confounded by age, sex, type of food, level of specific IgE, eliciting dose, 
history of asthma, atopic dermatitis, and rhinoconjunctivitis. This significant association 
also was seen in the subgroup of patients with a positive history but a negative food chal-
lenge outcome (B=-0.15, 95% CI:-3.75 to -0.66, P=0.005) but, remarkably, not for children 
with a positive history and a positive food challenge outcome (B=-0.05, 95% CI:-2.24 to 
0.72, P=0.313). 
The concentration of ApoB was not associated with the food challenge outcome (adjusted 
odds ratio= 0.90, 95% CI: 0.41 to 1.98, P=0.790) or the severity of the DBPCFC reaction (B 
=-0.01, 95% CI:-1.17 to 1.02, P=0.894). All association models used for the analysis met the 
assumptions of the test. To examine whether the outliers (the 10 cases outside the CI) had 
an effect on the outcome, the data were reanalyzed with these cases excluded. However, 
this analysis showed no difference in the results, and the inverse association between 
ApoB and the severity of the accidental reaction remained unchanged (data not shown).
DiScuSSion
This study has, for the first time, shown an association between ApoB and the severity of 
the accidental reaction in children with suspected food allergy. The results of this study 
suggest that ApoB might be a biomarker for the severity of anaphylactic reactions, prob-
ably by virtue of its association with the less stable PAF-AH. 
The finding that this marker is associated with severity of anaphylaxis in patients with 
negative food challenge outcomes is surprising but could be due to the fact that the sever-
ity of reactions to foods are governed to a larger extent by other factors such as type 
and dose of the ingested food, making the relation with ApoB more tenuous. A second 
conclusion suggested by this finding is that most patients with a negative food challenge 
outcome indeed experienced an anaphylactic event in the past. In view of the natural 
history of patients with negative food challenge outcomes, this finding suggests that such 
anaphylactic events do not seem to have an obvious allergic cause and do not tend to 
recur.
The association between ApoB and the severity of the accidental reaction is in agree-
ment with the previous findings concerning the role of PAF and PAF-AH in anaphylactic 
reactions. In contrast to PAF-AH, ApoB can be accurately determined from stored frozen 
serum samples and is more stable, convenient, and inexpensive to measure. Although 
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measurement of ApoB explains only a relatively small part of the anaphylactic risk, serum 
samples obtained closer to the time of the anaphylactic reaction and from patients with 
other forms of anaphylaxis might be more informative. Further studies on this topic are 
indicated to evaluate this biomarker in food-induced anaphylaxis and other types of ana-
phylaxis.
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